The Bio Report
Using AI to Discover Small Molecule Alternatives to Biologics
Nov 6, 2024
Kfir Schreiber, Co-founder and CEO of Deepcure, specializes in AI-driven small molecule therapies for autoimmune diseases. He discusses how AI is revolutionizing drug discovery by exploring previously unreachable chemical spaces. The conversation delves into the shift from biologics to small molecules, emphasizing their advantages in treatment. Kfir also highlights Deepcure's innovative techniques in generating effective inhibitors, showcasing the potential to turn challenging targets into viable therapies while reducing toxicity and improving patient outcomes.
31:33
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- DeepCure's AI-driven platform enables the discovery of small molecule therapies, targeting previously undruggable proteins for autoimmune diseases.
- By integrating advanced physics simulations with AI, DeepCure enhances drug design efficiency and improves the safety profile of developing compounds.
Deep dives
AI in Drug Discovery
The potential of artificial intelligence (AI) is reshaping drug discovery by enabling exploration of a broader chemical space. DeepCure is focused on using AI to discover small molecule therapies for autoimmune diseases, addressing challenges that traditional methods have struggled with. By leveraging advanced physics simulations alongside AI, DeepCure identifies numerous binding opportunities for potential drug molecules, reducing design biases typically present in traditional approaches. This innovative methodology not only enhances the efficiency of the discovery process but also improves the likelihood of developing effective, safe small molecule drugs.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
